Page 5 - Down Syndrome Center News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Down syndrome center. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Down Syndrome Center Today - Breaking & Trending Today

ProMIS Neurosciences Inc.: ProMIS Neurosciences appoints renowned neuroscientist, Dr. Rudolph Tanzi, as Chair of Scientific Advisory Board


(0)
TORONTO and CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced the appointment of Rudolph Tanzi, Ph.D, as Chair of the Company s scientific advisory board (SAB). Dr. Tanzi is the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard University and Vice-Chair of Neurology, Director of the Genetics and Aging Research Unit, and Co-Director of the Henry and Allison McCance Center for Brain Health at Massachusetts General Hospital. ....

New York , United States , Memorial Sloan Kettering Cancer Center , United Kingdom , Cold Spring Harbor Laboratory , San Diego , City Of , Rudy Tanzi , Florence Riford , C Warren Olanow , Sharon Cohen , Neilr Cashman , Eugene Williams , Nicholas Rigopulos , Neil Cashman , Williamc Mobley , Joe Perry , Andre Strydom , David Wishart , Michellel Hastings , Rudolph Tanzi , King College London , Department Of Neuroscience , Research Unit , University Of British Columbia , Royal Institute Of Technology ,

Annovis Bio, Inc.: Annovis Bio to Study Potential of ANVS401 to Normalize Brain Development in Down Syndrome


(1)
Collaborative mice study with UC San Diego to study brain development from embryo to old age
Berwyn, Pennsylvania (Newsfile Corp. - April 29, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer s disease (AD), Parkinson s disease (PD) and other neurodegenerative diseases, today announced a new research collaboration with Professor William Mobley and Dr. Xuqiao Chen at the University of California San Diego designed to study the ability of the Company s lead compound, ANVS401, to normalize brain development in Down Syndrome (DS) mice.
While we know quite a bit about how the brain degenerates in the later stages of life, extraordinarily little is known about how neurodegeneration may start very early in life. We, therefore, plan to look at the brain in embryonic development in DS mice, said Maria Maccecchini, Ph.D., Founder and Chief Executive Officer. ....

United States , San Diego , University Of California San Diego , William Mobley , Maria Maccecchini , Xuqiao Chen , Florence Riford , Annovis Bio , Down Syndrome Center , Alzheimer Research , Pennsylvania Newsfile Corp , Annovis Bio Inc , Journal Of The Alzheimer Association , Exchange Commission , Redchip Companies Inc , Uc San Diego School Of Medicine , Professor William Mobley , California San Diego , Down Syndrome , Chief Executive , Diego School , Florence Riford Chair , Annual Report , ஒன்றுபட்டது மாநிலங்களில் , சான் டியாகோ , பல்கலைக்கழகம் ஆஃப் கலிஃபோர்னியா சான் டியாகோ ,